SCHEDULE 13G/A 0000902664-23-001667 0001559706 XXXXXXXX LIVE 1 Common stock, par value $0.001 per share 12/31/2024 0001645460 Cue Biopharma, Inc. 22978P106 40 GUEST STREET BOSTON MA 02135 Rule 13d-1(b) Slate Path Capital LP DE 0.00 918836.00 0.00 918836.00 918836.00 N 1.4 IA PN Includes 918,836 shares of Common Stock (as defined in Item 2(a)) issuable upon exercise of warrants David Greenspan X1 0.00 918836.00 0.00 918836.00 918836.00 N 1.4 HC IN Includes 918,836 shares of Common Stock issuable upon exercise of warrants Cue Biopharma, Inc. 40 Guest Street, Boston, MA 02135 This statement is filed by: (i) Slate Path Capital LP (the "Investment Manager"), a Delaware limited partnership and the investment manager of Slate Path Master Fund LP (the "Master Fund"), a Cayman Islands exempted limited partnership, and SPB Master Fund LP, a Cayman Islands exempted limited partnership (the "SPB Master Fund", and, together with the Master Fund, the "Slate Path Funds"), with respect to the shares of common stock, par value $0.001 per share (the "Common Stock") of Cue Biopharma, Inc. (the "Company"), issuable upon exercise of warrants directly held by the Slate Path Funds; and (ii) David Greenspan ("Mr. Greenspan"), the managing partner of Jades GP, LLC, a Delaware limited liability company and the general partner of the Investment Manager, with respect to the shares of Common Stock issuable upon exercise of warrants directly held by the Slate Path Funds. The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons". The filing of this statement should not be construed as an admission that any of the forgoing persons or any Reporting Person is, for the purposes of Section 13 of the Act, the beneficial owner of the securities reported herein. The address of the business office of each of the Reporting Persons is 717 Fifth Avenue, 16th Floor, New York, NY 10022. The Investment Manager is a Delaware limited partnership. Mr. Greenspan is a citizen of the United States. N IA HC The information required by Item 4(a) is set forth in Row 9 of the cover page for each of the Reporting Persons and is incorporated herein by reference. The percentages set forth in this Schedule 13G are calculated based upon an aggregate of 63,350,327 shares of Common Stock outstanding as of November 12, 2024, as reported in the Company's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2024, filed with the Securities and Exchange Commission on November 14, 2024, and assumes the exercise of warrants reported herein. 1.4 The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for each of the Reporting Persons and is incorporated herein by reference. The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for each of the Reporting Persons and is incorporated herein by reference. The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for each of the Reporting Persons and is incorporated herein by reference. The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for each of the Reporting Persons and is incorporated herein by reference. N Y N See Item 2(a). The Slate Path Funds have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the shares of Common Stock reported herein. Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. Slate Path Capital LP /s/ John Metzner 02/14/2025 David Greenspan /s/ Jim Feeney 02/14/2025 * Pursuant to a Power of Attorney, dated as of July 31, 2020, attached as Exhibit 2 to that certain Schedule 13G filed with the Securities and Exchange Commission on February 14, 2023 by the Investment Manager.